Pharmacogenetics the treatment of epilepsy








The clinical impact of pharmacogenetics on the treatment of epilepsy

6/18/2014
03:41 | Author: Steven Lewis

Seizure control medications
The clinical impact of pharmacogenetics on the treatment of epilepsy

Drug treatment of epilepsy is characterized by unpredictability of the ultimate goal of pharmacogenetics is to use the genetic makeup of an.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

This article reviews the published work with particular emphasis on pharmacogenetic alterations that may affect efficacy, tolerability, and safety of antiepileptic drugs (AEDs), including variation in genes encoding drug target (SCN1A), drug transport (ABCB1), drug metabolizing (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins. Although genetic testing raises ethical and social issues, a better understanding of the genetic influences on epilepsy outcome is key to developing the much needed new therapeutic strategies for individuals with epilepsy. Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B*1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Since genetic variability in drug metabolism was reported to affect the treatment with phenytoin more than 25 years ago, the ultimate goal of pharmacogenetics is to use the genetic makeup of an individual to predict drug response and efficacy, as well as potential adverse drug events. Drug treatment of epilepsy is characterized by unpredictability of efficacy, adverse drug reactions, and optimal doses in individual patients, which, at least in part, is a consequence of genetic variation. However, determining the practical relevance of pharmacogenetic variants remains difficult, in part because of problems with study design and replication.

Generate a file for use with external citation management software.

Warning: The NCBI web site requires JavaScript to function. more.

Comments (0)



The potential of pharmacogenetics in the treatment of epilepsy

4/17/2014
01:42 | Author: Chloe Allen

Seizure control medications
The potential of pharmacogenetics in the treatment of epilepsy

It is hoped that ultimay, findings in epilepsy pharmacogenetics will lead to a more efficacious and less harmful treatment of epilepsy, development of more.

Comments (0)

Pharmacogenetics in Epilepsy Treatment Sense or Nonsense?

12/26/2014
09:37 | Author: Molly Young

Seizure control medications
Pharmacogenetics in Epilepsy Treatment Sense or Nonsense?

AED treatment is often problematic because of unpredictability of drug response. An increasing number of pharmacogenetic association studies in epilepsy.

Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site.

Medscape: Medscape Access In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.

Comments (0)

Pharmacogenetics in Epilepsy Treatment Sense or - Medscape

10/25/2014
07:04 | Author: Allison King

Seizure control medications
Pharmacogenetics in Epilepsy Treatment Sense or - Medscape

AED treatment is often problematic because of unpredictability of drug response. Could pharmacogenetics hold the key?.

Medscape: Medscape Access In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.

Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site.

Comments (0)

The clinical impact of pharmacogenetics on the treatment of epilepsy

8/24/2014
05:35 | Author: Molly Young

Medications to treat seizures
The clinical impact of pharmacogenetics on the treatment of epilepsy

Drug treatment of epilepsy is characterized by unpredictability of efficacy, adverse drug reactions, and optimal doses in individual patients.

Increased expression of Pgp and other drug efflux transporters has been determined in epileptogenic brain tissue of patients with refractory epilepsy ( Fig. In rodent models of temporal lobe epilepsy (TLE), the increased Pgp expression in the hippocampus and parahippocampal regions was associated with significantly decreased concentrations of AEDs in these regions ( Rizzi et al., 2002 ; Van Vliet et al., 2007 ). In patients with oxcarbazepine (OXC)-resistant epilepsy, the brain tissue expression of ABCB1 mRNA was found to be inversely correlated with brain levels of 10,11-dihydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide (10-OHCBZ), the active metabolite of OXC, indicating that Pgp may play a role in the pharmacoresistance to OXC by causing insufficient concentrations of its active metabolite at neuronal targets ( Marchi et al., 2005 ).

Comments (5)Read more